HALOZYME THERAPEUTICS (HALO) 8-K Summary (Nov 3, 2025)

This Form 8-K discloses material management changes and the announcement of recent financial performance.

• CFO Departure: SVP and CFO Nicole LaBrosse is transitioning out, expected to leave by March 30, 2026, or upon hiring a successor.

  • The separation is not due to any disagreement regarding financial statements or internal controls.
  • The Company has initiated a search for the next CFO.

• Financial Results: The Company furnished its press release detailing Q3 2025 financial results (Item 2